BRD4 and neoplasm: As previously seen, the administration of PLX51107 in combination with anti–PD-L1 in LLC tumor–bearing BRD4 WT mice led to a significant reduction in tumor volumes compared with anti–PD-L1 therapy alone (Figure 7, B and C; P < 0.0001).